ESC 365 - Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device.

ESC Premium Access

Long-term survival of low- and intermediate risk TAVI-patients: a real world, single center comparison of 684 patients treated with the sapien 3 or the sapien XT device.

Session: Poster session 1 - Risk stratification and prognosis after TAVI

Topic: Aortic valve disease

Speaker: Mr J. Vendrik (Amsterdam, NL)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Mr Jeroen Vendrik

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

0 follower

10 more presentations in this session

Effect of transcatheter aortic valve implantation (TAVI) in acquired von Willebrand syndrome and molecular analysis of high-molecular-weight multimers.

Speaker: Doctor M. Perrone (Rome, IT)

Combination of pre-existing atrial fibrillation and coronary artery disease associates with poor outcome in patients who undergo TAVI

Speaker: Doctor H. Hioki (Tokyo, JP)

Transcatheter aortic valve replacement alters expression levels of circulating myocardial microRNAs

Speaker: Doctor F. Jansen (Bonn, DE)

Cardiac biomarkers and clinical scores for risk stratification in patients with severe symptomatic aortic stenosis undergoing TAVI. Which ranks first now?

Speaker: Mrs A. Stundl (Bonn, DE)

Peri-procedural myocardial injury depends on transcatheter heart valve type but does not predict mortality in patients after tavi

Speaker: Mrs A. Stundl (Bonn, DE)

Access the full session

Poster session 1 - Risk stratification and prognosis after TAVI

Speakers: Mr J. Vendrik, Doctor M. Perrone, Doctor H. Hioki, Doctor F. Jansen, Mrs A. Stundl...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources